|
EP3755361A1
|
|
Methods of treating nash and compositions therefore
|
|
AU2018304200A1
|
|
Peptides and methods of transplantation and restorative organ function
|
|
US2020000874A1
|
|
Peptides and methods of treating dystrophy-related disorders using the same
|
|
CN110869044A
|
|
Peptides and methods of treating malnutrition-related disorders with peptides
|
|
CA3004055A1
|
|
Peptides and methods of treating endometriosis using the same
|
|
CA2996874A1
|
|
Compositions and methods for the treatment of neurodamage
|
|
EP3341739A1
|
|
Mutant peptides and methods of treating subjects using the same
|
|
AU2015343202A1
|
|
PIF binding as a marker for immune dysregulation
|
|
US2017336406A1
|
|
Pif binding as a marker for immune dysregulation
|
|
CA2961375A1
|
|
Compositions and methods for treating acute radiation syndrome
|
|
CA2928411A1
|
|
Pif-transfected cells and methods of use
|
|
US2008269137A1
|
|
Compositions and methods for modulating the immune system
|
|
US2008003178A1
|
|
PIF tetrapeptides
|
|
EP1680442A2
|
|
Pif peptides biologic activities
|
|
NZ578577A
|
|
Pif peptides biologic activities, site of action, and the antibody to detect pif
|
|
CA2584690A1
|
|
Pif peptides biologic activities, site of action, and the antibody to detect pif
|
|
CN1522306A
|
|
New assays for preimplantation factor and preimplantation factor peptides
|
